Home › Compare › IRCWF vs ABBV
IRCWF yields 14492.75% · ABBV yields 3.06%● Live data
📍 IRCWF pulled ahead of the other in Year 1
Combined, IRCWF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IRCWF + ABBV for your $10,000?
IRC Limited, an investment holding company, develops, produces, and sells industrial commodities products in the Russia, People's Republic of China, and internationally. The company operates through four segments: Mines in Production, Mines in Development, Engineering, and Other. The Mines in Production segment comprises iron ore projects in production phase, which include the Kimkan and Sutara project located in the Obluchenskoye district of the Jewish Autonomous Region in the Russian Far East. The Mines in Development segment consists of iron ore projects in the exploration and development phase comprising the Garinskoye project that focuses on iron ore deposits in the Amur region; Kostenginskoye project; and the Bolshoi Seym project that explores for ilmenomagnetite, magnetite, and ilmenite located in the located in the Tynda district of Amur region in the Russian Far East region. The Engineering segment provides technical mining research and consultancy services. The Other segment engages in the production of vanadium pentoxides and related products, and other projects. It is also involved in the provision of general trading, financing, engineering, and procurement services; and development of titanium sponge. The company was incorporated in 2010 and is headquartered in Central, Hong Kong.
Full IRCWF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.